BOSTON, Oct 20- Billionaire investor William Ackman, whose fund is the largest shareholder in Allergan Inc., and Valeant Pharmaceuticals said the botox maker's Chief Executive Officer David Pyott tried to discredit Valeant as it was making a hostile takeover bid, court documents showed. Ackman's hedge fund has been working with Valeant for months to craft a...» Read More
Activist investor Carl Icahn reported a 12.63 stake in medical device maker Hologic, prompting the company to seek protection from a hostile takeover
With a takeover of Blackberry looming, CNBC's Jim Cramer says the security and intellectual property of Blackberry is invaluable.
CNBC's Kayla Tausche reports Twitter is staggering its board so it is less susceptible to a takeover.
BlackBerry has underperformed recently, while Microsoft is on a tear. Peter Misek of Jefferies, weighs in on whether Microsoft should buy BlackBerry.
CNBC's David Faber reports the latest details on Michael Dell and Silver Lake's attempts to take the PC maker private, and provides an update on Community Health's attempts to acquire Health Management Associates for $3.9 billion.
Despite the postponement of the shareholder vote, David Eaton, Vice President of Proxy Research at Glass Lewis, says 11th-hour backing from some large investors shows there is more support for Michael Dell's buyout plan than initially thought.
One person with a lot at stake in the Dell shareholder decision is Carl Icahn, reports CNBC's Scott Wapner.
Dell shareholder Norm Peters provides perspective on the adjournment of Dell's shareholder meeting and the future of the PC maker.
According to Reuters it appears Michael Dell does not have enough shareholder votes to take his company private, reports CNBC's Andrew Ross Sorkin.
CNBC's Jackie DeAngelis provides a preview of what to expect from today's possible shareholder vote on Michael Dell and Silver Lake's proposed acquisition of the PC maker. And Scott Wapner has an update on Carl Icahn's opposition to the deal, with Joe Weisenthal, Business Insider executive editor.
Evan Staples, Nuveen Asset Management, discusses the likelihood of Pepsi making a run for Mondelez.
Kenneth Squire, 13-D Monitor, shares his thoughts on shareholder activism and discusses the likely fate of Michael Dell's plans to take his company private, as activist investor Carl Icahn fuels opposition to the deal.
CNBC's Scott Wapner has the update on Carl Icahn's bid for the PC maker. And Joe Weisenthal, Business Insider executive editor, shares his thoughts on the battle for Dell.
Billionaire investor Carl Icahn once again upped the ante in his bid for the PC maker, as shareholders may vote today on whether to take the company private. Carr Lanphier, Morningstar analyst, weighs in on the deal.
Larry Fishelson, co-founder & CEO of Dynalink and Mark O'Hare, CEO of Preqin, discuss Dell ahead of a shareholders' vote on a private takeover and what it would mean for the group to go private.
Activist investor Carl Icahn announced he will enhance his offer to buy the PC maker for a proposed $14 per share, plus one warrant, reports CNBC's David Faber.
Senators sought answers from Smithfield CEO on whether the its proposed sale to China's largest pork producer could hurt U.S. food safety and raise prices for American consumers.
Short-term takeover targets have some "potholes," says Mario Gabelli of the Gabelli Funds, providing his play on Hillshire Farm, Post and Navistar. And a technical look at what the charts are indicating about the markets, with Stephen Suttmeier, Bank of America.
Japanese mobile carrier Softbank's bid for Sprint was approved by US Federal Communications Commission last week, clearing the way for the firm to create a foothold in the US market. The Nikkei's Makiko Utsuda has more.
Onyx Pharmaceuticals has rejected a $10 billion takeover bid from Amgen, reports CNBC's Bertha Coombs.